7129.T
The company operates in the healthcare sector, providing biotechnology services and equipment, and generates revenue primarily through the sale of healthcare products and services.
Business. The company operates in the healthcare sector, providing biotechnology services and equipment, and generates revenue primarily through the sale of healthcare products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, providing biotechnology services and equipment, and generates revenue primarily through the sale of healthcare products and services.
The company's capital structure is characterized by a debt-to-equity ratio of 0.89, indicating a moderate level of leverage. Its liquidity position is assessed as medium, with a current ratio of 0.84, suggesting that the company may face challenges in meeting its short-term obligations. The company's price-to-book ratio is 0.83, which is below 1, indicating that the market value is less than the book value of the company's equity.
In terms of profitability, the company's return on equity (ROE) is 0.079, which is relatively low compared to industry standards. The return on assets (ROA) is 0.0226, further indicating that the company is not efficiently utilizing its assets to generate profits. The operating margin, calculated as operating income divided by revenue, is 0.0202, which is also below the industry median.
The company's revenue is primarily concentrated in the healthcare services and equipment segment, with no significant geographic diversification disclosed. The financial data does not provide specific segment or geographic revenue breakdowns, making it difficult to assess the extent of revenue concentration.
The company's growth trajectory is not clearly defined in the provided data. The outlook for the current fiscal year does not include specific numeric deltas for revenue growth. However, the company's operating cash flow of 1,010,807,000 JPY suggests a positive cash flow from operations, which could support future growth initiatives.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a liquidity challenge. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding.
Recent events and filings do not provide specific details on the company's recent activities. The analyst estimates for the last actual EPS and revenue are 113.95 JPY and 23,825,720,000 JPY, respectively, which align with the reported financial data.
- The company has a moderate level of leverage with a debt-to-equity ratio of 0.89.
- The company's ROE and ROA are below industry standards, indicating inefficiencies in asset utilization and profitability.
- The company's liquidity position is medium, with a current ratio of 0.84.
- The company's growth trajectory is not clearly defined, and there is no significant geographic diversification disclosed.
- The company faces a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 7129.T Market data — financials · 2026-05-27
- Miahelsa Holdings Corp Market data — analyst estimates · 2026-05-27